Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.39 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687958 | 0.86 | MDM2 (0.40) | AKR1C2AKR1C1FTOMDM2EPHB3 | |
| SCHEMBL3684406 | 0.86 | AKR1C4 (0.39) | AKR1C2AKR1C1DUSP3MDM2EPHB3 | |
| SCHEMBL3689623 | 0.83 | LDHA (0.43) | MDM2MAPTCTRC | |
| SCHEMBL3643185 | 0.82 | AKR1C2 (0.36) | AKR1C2AKR1C1FTOMDM2EPHB3 | |
| SCHEMBL3696358 | 0.81 | BCL2L1 (0.39) | MDM2CTRC | |
| SCHEMBL3689479 | 0.81 | CYP19A1 (0.43) | — | |
| SCHEMBL3696360 | 0.81 | BCL2L1 (0.39) | MDM2CTRC | |
| SCHEMBL3699155 | 0.80 | SERPINE1 (0.36) | DUSP3MDM2 | |
| SCHEMBL3690129 | 0.78 | AKT1 (0.41) | MDM2 | |
| SCHEMBL3687376 | 0.78 | GRM2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | AKR1C2 2053/4885AKR1C1 2391/4885FTO 3910/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | AKR1C2 2053/4885AKR1C1 2391/4885FTO 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.